Stock Taper Adjusted Net Revenues: $470 million, a 22% increase year-over-year.
Operating Income: $94 million, with an operating margin of 20%.
Adjusted EPS: $1.
Corporate Investment Banking Revenues: $324 million, up 30% year-over-year.
Advisory Revenues: Record high of $251 million, up 16% year-over-year.
Corporate Financing Revenues: $73 million, a 122% increase from the prior year.
Compensation Ratio: 61.6%, improved by 90 basis points year-over-year.
Shareholder Returns: $171 million returned, including $101 million in dividends and $70 million in share repurchases.
Achieved a record in Corporate Investment Banking, driven by strong corporate financing and advisory services.
Healthcare franchise performed exceptionally well, with notable contributions from medtech and biopharma sectors.
Ranked as the top adviser in U.S. medtech M&A and #1 in U.S. bank M&A by deal value.
Continued investment in talent, with a record number of managing directors and strategic hires in key sectors.
Positive momentum in Private Capital Advisory and Debt Capital Markets Advisory, contributing to overall growth.
Expect second quarter advisory revenues to be similar to Q1, with a cautious outlook on corporate financing revenues, anticipating a decline from the strong first quarter.
Public Finance revenues are expected to improve modestly in Q2, aligning with seasonal trends.
Equity brokerage revenues are projected to decline from record levels due to expected lower market volatility.
Overall, the company remains focused on maintaining strong margins and leveraging its comprehensive product capabilities.
The macroeconomic environment remains uncertain, impacting the pace of bank M&A activity, which is slower than anticipated.
Advisory services may see a slowdown, particularly in sectors like banking and healthcare, with some caution from sponsors regarding launching new transactions.
Fixed income revenues face challenges due to market volatility and geopolitical factors, leading to a slow start in Q2.
A significant litigation-related expense of $8.5 million impacted non-compensation costs.
Management noted a slowdown in bank M&A activity and highlighted the need for stability in the market to encourage transactions.
Concerns were raised about the impact of volatility on hedging activities and the overall fixed income market.
The Technology sector is experiencing caution due to AI disruptions and valuation concerns, which may slow M&A activity.
The company expressed optimism about the private capital advisory business, which is gaining traction and contributing positively to revenues. Overall, Piper Sandler reported a strong start to 2026, with significant growth in key areas, but faces challenges from market volatility and a cautious outlook on certain advisory segments.
SOURCE: Q1 2026 EARNINGS CALL TRANSCRIPT